Subtle Medical, the Menlo Park-based startup founded by Stanford researchers, just secured $33 million in Series C funding—marking a pivotal moment as the company positions its AI-powered imaging platform to reach hospitals and health systems around the world. The investment, led by Morgan Stanley Expansion Capital with backing from Shinhan Venture Investment, Samsung Ventures, and other existing backers, brings the company's total funding to $86 million and signals strong confidence in the technology's potential to reshape how medical imaging works at scale.
The company has developed a deceptively elegant solution to a stubborn problem in modern healthcare: medical imaging is slow, expensive, and requires equipment upgrades that many hospitals cannot afford. Subtle Medical's vendor-neutral artificial intelligence software does something different. Rather than requiring hospitals to replace their MRI, PET, or CT scanners, the company's tools enhance image quality and dramatically accelerate scan times on equipment that already exists. The results speak for themselves—its MRI software enables facilities to complete scans up to 80% faster, while its PET imaging solutions support lower-dose and faster imaging, reducing patient exposure to radiation while freeing up scanner time for more patients.
With leadership transitions underway, the company is entering a new phase of growth. Co-founder and CEO Enhao Gong, Ph.D., is stepping into the role of Chief Science Officer, where he will guide the company's scientific strategy and continue supporting operations in China. Taking the helm as CEO is Ohad Arazi, a healthcare technology executive who brings two decades of experience from leadership positions at companies including Clarius, Zebra Medical Vision, Genoox, TELUS Health, and Change Healthcare. Arazi's arrival signals a shift in focus toward aggressive commercial expansion and operational scaling.
The evidence of traction is already striking. Subtle Medical's AI tools are currently running on more than 1,300 scanners worldwide across health systems, imaging networks, and academic medical centers. The company has earned 11 U.S. Food and Drug Administration clearances and published more than 25 peer-reviewed research papers—a credential rarely seen in AI health-tech companies and one that reflects the scientific rigor behind its claims. The company is also advancing new territory: it's partnering with Bracco Imaging on AI-enabled contrast imaging technologies and developing new CT imaging solutions with FDA clearance pending.
Arazi has outlined an ambitious vision for what comes next. The focus will be on expanding adoption among hospitals and health systems while increasing imaging capacity using the infrastructure they already own. This resonates with hospital administrators facing budget constraints and equipment limitations. Subtle Medical is targeting break-even profitability within the next 24 months as it moves into new markets and customer segments—a timeline that suggests the company believes it has found product-market fit and is ready to scale.
What makes this investment moment worth watching is not just the funding amount, but the problem it's solving. Healthcare systems globally are straining under imaging demand, and radiologists are overworked. Subtle Medical offers a path to more throughput without requiring the massive capital expenditures that typically come with healthcare modernization. With the right leadership and resources now in place, the company appears ready to prove whether this technology can reshape imaging at the scale where it truly matters—inside the hospitals and clinics where patients actually need it.